Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Status:
Recruiting
Trial end date:
2023-01-15
Target enrollment:
Participant gender:
Summary
This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab
works in treating patients with CD30+ lymphoma that has come back after a period of
improvement or does not respond to treatment. Biological therapies, such as brentuximab
vedotin, may stimulate the immune system in different ways and stop cancer cells from
growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor
cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work
better in treating patients with CD30+ lymphoma.